Slide 1: Q2 2026 Earnings Deck
Q2 2026 Earnings Deck August 6th, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements Forward-Looking Statements Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking stateme
Slide 3: Cryoport – Trusted Partner to Life Sciences Companies
Cryoport – Trusted Partner to Life Sciences Companies Life sciences company focused on providing mission critical, proprietary temperature-controlled supply chain solutions Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature-controlled state such
Slide 4: Cryoport Snapshot – By the Numbers
Cryoport Snapshot – By the Numbers Leading integrated platform ensuring the integrity of critical biomaterials across the life sciences value chain $49M $192-$196M 46.6% $0.4M +8% Organic Growth +9-11% Organic Growth $1.3M Improvement YoY Q2 FY2026 FY2026 Q2 FY2026 Q2 FY2026 Adjusted Revenue Updated
Slide 5: Revenue from supporting Commercial Cell and Gene Therapies
Revenue from supporting Commercial Cell and Gene Therapies Q1 2024 through Q2 2026 © 2026 CRYOPORT, INC. 5
Slide 6: Q2 Life Sciences Services Overview
Q2 Life Sciences Services Overview © 2026 CRYOPORT, INC. 6
Slide 7: Q2 2026 Revenue Drivers
Q2 2026 Revenue Drivers Strong double-digit growth across the platform of services +25% +26% Commercial BioServices & Cell & Gene +15% Biostorage Therapy Revenue Services Revenue Life Sciences Services Revenue Q2 FY2026 Revenue Strong Growth +8% Total revenue (Year over Year) Across All Services © 2
Slide 8: Cell Therapy Market Growing 28% Through 2030
Cell Therapy Market Growing 28% Through 2030 (Includes Cell and CAR-T Therapies) © 2026 CRYOPORT, INC. 8
Slide 9: CGT Industry Funding ($ bil.)
CGT Industry Funding ($ bil.) © 2026 CRYOPORT, INC. 9
Slide 10: Growth in U.S. CGT Claims and Treatment Centers
Growth in U.S. CGT Claims and Treatment Centers (2018 vs. 2025) Source: Alliance for Regenerative Medicine Whitepaper - Cell & Gene Therapy Expansion: The Evolution of CGT Delivery in the U.S. – June 2026 © 2026 CRYOPORT, INC. 10
Slide 11: Patients First: Supporting the Therapies of Tomorrow
Patients First: Supporting the Therapies of Tomorrow Clinical Trials Supported, by Trial Phase Phase I Phase II Phase III 900 766 779 760 800 701 94 654 675 86 91 700 602 81 79 82 600 528 74 69 361 357 369 500 300 311 321 273 400 239 300 200 282 299 313 318 316 255 275 220 100 0 2020 2021 2022 2023
Slide 12: Supporting 23 Commercial Cell and Gene Therapies Globally
Supporting 23 Commercial Cell and Gene Therapies Globally アクーゴ AKUUGO® ® © 2026 CRYOPORT, INC. 12
Slide 13: Cryoport, Inc. Global Locations
Cryoport, Inc. Global Locations Amsterdam, NL Global Logistics Center Morris Plains, NJ Global Supply Chain Center Irvine, CA Stevenage, UK Tokyo, Japan Supply Chain Hub Global Logistics Center Global Logistics Center Darmstadt, DE Tec4Med Lifescience New Prague, MN Chengdu, China Manufacturing Faci
Slide 14: Cryoport Supported Clinical Trials by Phase
Cryoport Supported Clinical Trials by Phase Cryoport Supported Clinical Trials by Region June 30, June 30, Clinical Trials Clinical Trials 2025 2024 2025 2026 Phase 1 304 Americas 525 556 579 Phase 2 342 EMEA 114 124 145 Phase 3 82 APAC 45 43 55 Total Total ©2026 CRYOPORT, INC.
Slide 15: Cryoport, Inc. and Subsidiaries
Cryoport, Inc. and Subsidiaries Revenue Three Months Ended Six Months Ended June 30, June 30, (unaudited) (unaudited) (in thousands) 2026 2025 % Change 2026 2025 % Change Life Sciences Services $ 27,969 $ 24,369 15% $ 54,867 $ 47,234 16% BioLogistics Solutions 22,359 19,874 13% 44,027 38,404 15% Bio
Slide 16: Condensed Consolidated Statements of Operations
Cryoport, Inc. and Subsidiarios Condensed Consolidated Statements of Operations Investment income 332 1.65 6.222 3.030 interest expense 18) (618) (30) 20a) (Other expense, net 63) (2339) (2593) 8239) ‘Loss before provision for income taxes 7750) (2.720) (774 (3.244) Net income loss attributable to c
Slide 17: Condensed Consolidated Balance Sheets
Cryoport, Inc. and Subsidiaries Condensed Consolidated Balance Sheets December 34, 2025, “in ehowsands) (unaudited) Current assets ‘Cash and cash equivalents $ 269,267 § 250,494 ‘Short-term investments 121,426 160,714 ‘Accounts receivable, net 33,359 Inventories 23,188 Prepaid expenses and other cur
Slide 18: Reconciliation of GAAP loss from continuing operations to adjusted EBITDA
Cryoport, Inc. and Subsidiaries Reconciliation of GAAP loss from conti ing operations to adjusted EBITDA (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025 (in thousands) GAAP loss from continuing operations $ (8255) $ (12,014) $ (17,687) $ (18,752) Non-GAAP adjust
Slide 19: Driving Bottom-Line Improvement
Driving Bottom-Line Improvement 46.6% $0.4M $397M Gross Margin Adjusted EBITDA Cash and from Continuing from Continuing Short-Term Operations Operations Investment © 2026 CRYOPORT, INC. 19